Early benefit assessment of seven interventional procedures by the IQWiG in Germany

09

Jun 2021

For the first time in three years, the Institute for Quality and Efficiency in Health Care (IQWiG) received data within the framework of the early benefit assessment of new examination and treatment methods (NUB) with high-risk medical devices according to §137h of Social Code Book (SGB) V. This involves seven invasive therapeutic cardiovascular, pulmonary, neurological, gastrointestinal, and urological procedures.

The IQWiG and the Federal Joint Committee (G-BA) evaluated the clinical data for each of these methods, which had in each case been compiled by the hospital and the medical device manufacturer. In some cases, the manufacturer had already started its own study, so that the main decision to be made was whether an additional study in Germany was reasonable.

For six of the seven invasive procedures, due to a lack of meaningful data, no robust conclusions can be drawn on the benefit, harm, or ineffectiveness for patients. IQWiG developed key points for co-funded studies in each case unless promising studies are already being conducted. However, the data indicate a benefit for transcranial magnetic resonance-guided focused ultrasound (TK-MRgFUS) in patients with essential tremor who are ineligible for deep brain stimulation (DBS).

An overview of the early benefit assessment results for the considered procedures is provided below:

  • Transcranial magnetic resonance-guided focused ultrasound for essential tremor: In patients ineligible for DBS, a randomized controlled trial (RCT) showed advantages of TK-MRgFUS versus placebo or no treatment for some outcomes: tremor, activities of daily living, and health-related quality of life. Therefore, based on the documents available, a benefit of TK-MRgFUS versus conservative treatment alone can be identified. To a limited extent, these results can also be applied to patients who are eligible for DBS. Ultimately, however, it is questionable whether someone with severe tremor benefits at least from the targeted destruction of brain tissue using TK-MRgFUS as from the implantation of a DBS probe. To be able to answer this question, a comparative testing study would be helpful – possibly supplemented by data from a disease registry
  • A drug-coated balloon catheter (DBC) for urethral strictures: Overall, the evidence on this method versus the evidence on already existing treatment options is too sparse to be able to make an assessment. A testing study could provide the necessary findings for the benefit assessment of the method. As it is still unclear whether a study already underway abroad (ROBUST-III) is suitable for a benefit assessment, the IQWiG has designed key points for a testing study in Germany to examine the benefit of urethral DCB versus urethrotomia interna in men with short strictures in the anterior urethra. Since a urethral DCB is less invasive than urethroplasty, when comparing these two procedures, it is sufficient to demonstrate that urethral DCB is non-inferior to urethroplasty in men with symptomatic short and radiogenically induced urethral stenosis. RCTs with 100 to 500 patients are needed for both populations
  • Irreversible electroporation (IRE) for chronic bronchitis: Due to insufficient evidence, no conclusions can be inferred as to the advantages and disadvantages of IRE. Before starting a testing study in Germany, the IQWiG recommends awaiting the results of a promising study that has just begun abroad (RheSolve in Europe, the USA, and Canada)
  • Endoscopic duodenal mucosal resurfacing (DMR) for type 2 diabetes: The four studies available only provide data on the frequency of (severe) side effects. However, a testing study could provide the findings needed for a benefit assessment: To be able to prove a difference in the diabetes remission rate, a medium-sized RCT comparing DMR and conservative treatment would be required
  • Percutaneous implantation of an interatrial shunt for the treatment of heart failure: Of the three ongoing RCTs, the RELIEVE-HF study (with several German study centers) seems particularly suitable: If the study is conducted and completed as planned and provides usable analyses, the findings needed for the benefit assessment of percutaneous implantation of an interatrial shunt in patients with heart failure and limited pump function could be available in the foreseeable future. A separate testing study would then not be required
  • Coronary lithoplasty for coronary heart disease: Due to a lack of comparative data, no sound findings on the effect of coronary intravascular lithoplasty can be derived from the study results. Currently, severely calcified constrictions in coronary vessels are pre-treated using other procedures such as reaming (rotablation). A testing study in the form of an RCT with patients with calcified, non-pretreated coronary stenoses and a medical indication for percutaneous coronary intervention could provide the scientific basis for a benefit assessment. The study objective would be to compare coronary intravascular lithoplasty with alternative pre-treatment procedures to prevent serious cardiovascular events
  • Endovascular stent-graft for tricuspid regurgitation: Due to a lack of comparative data, the advantages and disadvantages of the method remain unclear. To demonstrate a difference in health-related quality of life, a medium-sized RCT comparing endovascular implantation of the stent-graft with sham treatment would be required as a testing study

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

21

Jun 2021

On June 16, 2021, the Institute for Quality and Efficiency in Health Care (IQWiG) has opened the submission period for proposals for topics of the health technology assessment (HTA) reports to be developed in 2022.

Read more

18

Jun 2021

In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.

Read more

17

Jun 2021

In late May 2021, the Treatment Council (Behandlingsråd), a new framework for assessing treatments and health technologies in Denmark, started accepting applications for the assessment of health technologies.

Read more

16

Jun 2021

The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.

Read more

15

Jun 2021

The National Institute for Health and Care Excellence (NICE) is currently developing health technology assessments concerning in-vitro diagnostics in its Diagnostic Guidance and Medtech Innovation Briefing programs. As of June 08, 2021, there are ten ongoing assessments.

Read more